ATE340177T1 - 12,13-modifizierte epothilon-derivate - Google Patents

12,13-modifizierte epothilon-derivate

Info

Publication number
ATE340177T1
ATE340177T1 AT99916383T AT99916383T ATE340177T1 AT E340177 T1 ATE340177 T1 AT E340177T1 AT 99916383 T AT99916383 T AT 99916383T AT 99916383 T AT99916383 T AT 99916383T AT E340177 T1 ATE340177 T1 AT E340177T1
Authority
AT
Austria
Prior art keywords
epothilone derivatives
modified epothilone
modified
derivatives
epothilone
Prior art date
Application number
AT99916383T
Other languages
English (en)
Inventor
Gregory D Vite
Soong-Hoon Kim Kim
Gerhard Hofle
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE340177T1 publication Critical patent/ATE340177T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT99916383T 1998-04-21 1999-04-05 12,13-modifizierte epothilon-derivate ATE340177T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8256498P 1998-04-21 1998-04-21

Publications (1)

Publication Number Publication Date
ATE340177T1 true ATE340177T1 (de) 2006-10-15

Family

ID=22171978

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99916383T ATE340177T1 (de) 1998-04-21 1999-04-05 12,13-modifizierte epothilon-derivate
AT99915273T ATE435861T1 (de) 1998-04-21 1999-04-05 12,13-cyclopropan-epothilonderivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99915273T ATE435861T1 (de) 1998-04-21 1999-04-05 12,13-cyclopropan-epothilonderivate

Country Status (17)

Country Link
US (2) US6380395B1 (de)
EP (3) EP1073648B1 (de)
JP (2) JP4476483B2 (de)
CN (1) CN1142923C (de)
AR (2) AR015774A1 (de)
AT (2) ATE340177T1 (de)
AU (2) AU748526B2 (de)
BR (1) BR9909795A (de)
CA (2) CA2323609A1 (de)
CY (2) CY1105836T1 (de)
DE (2) DE69933287T2 (de)
DK (3) DK1073648T3 (de)
ES (3) ES2400049T3 (de)
PE (1) PE20000460A1 (de)
PT (3) PT1589017E (de)
TR (1) TR200003036T2 (de)
WO (2) WO1999054319A1 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (de) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthese von Epitholonen, Zwischenprodukte, Analoga und ihre Verwendung
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
DE19826988A1 (de) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
ID29061A (id) * 1998-12-02 2001-07-26 Pfizer Prod Inc METODE DAN KOMPOSISI UNTUK MEMPERBAIKI STABILITAS KONFORMASI SUATU PROTEIN DARI KELUARGA p53
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
CA2368658A1 (en) * 1999-03-29 2000-10-05 Soong-Hoon Kim A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
EP2308833A3 (de) 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Zyklische Proteintyrosinkinaseinhibitoren
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6593115B2 (en) * 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
EP1414384A4 (de) 2000-10-13 2005-07-27 Univ Mississippi Synthese von epothilonen und verwandteln analoga
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
IL156580A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
ES2304240T3 (es) * 2001-01-25 2008-10-01 Bristol-Myers Squibb Company Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
AU2002245296B2 (en) * 2001-01-25 2006-12-21 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
BR0207487A (pt) 2001-02-20 2004-08-10 Brystol Myers Squibb Company Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
BR0207316A (pt) 2001-02-20 2004-02-10 Bristol Myers Squibb Co Derivados de epotilona para o tratamento de tumores refratários
RU2321400C2 (ru) * 2001-03-14 2008-04-10 Бристол-Маерс Сквибб Компани Композиция аналога эпотилона в сочетании с химиотерапевтическими агентами для лечения рака
EP1389209B1 (de) * 2001-04-24 2009-04-08 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
JP2004532888A (ja) 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
WO2003018002A2 (en) * 2001-08-23 2003-03-06 Novartis Ag Cyclopropyl and cyclobutyl epothilone analogs
WO2003026744A1 (en) * 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
AU2003218110A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7910594B2 (en) * 2002-05-15 2011-03-22 Endocyte, Inc. Vitamin-mitomycin conjugates
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2003105828A1 (en) * 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7256178B2 (en) * 2002-07-31 2007-08-14 Eisai Co., Ltd. Physiologically active substances
CA2494259A1 (en) * 2002-08-02 2004-02-19 Novartis Ag Epothilone derivatives
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1506203T3 (da) 2002-08-23 2007-05-14 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
MXPA05003006A (es) 2002-09-23 2005-06-22 Squibb Bristol Myers Co Metodos para la preparacion, aislamiento y purificacion de epotilona b y estructuras cristalinas de rayos x y de epotilona b.
US7091193B2 (en) * 2002-10-09 2006-08-15 Kosan Biosciences Incorporated Therapeutic formulations
CA2501610C (en) * 2002-10-11 2012-01-03 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
WO2004045518A2 (en) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
CA2512867C (en) 2003-01-27 2014-08-26 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
KR20060122819A (ko) * 2003-10-09 2006-11-30 코산 바이오사이언시즈, 인코포레이티드 치료학적 제형
US20050148543A1 (en) * 2003-10-09 2005-07-07 Michael Sherrill Therapeutic formulations
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1824458A1 (de) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Kügelchen mit magensaftresistentem überzug mit epothilon oder einem epothilon-analogon und seine herstellung und verabreichung
BRPI0518286A2 (pt) * 2004-11-18 2008-11-11 Bristol Myers Squibb Co microesfera com revestimento entÉrico contendo ixabepilona e sua preparaÇço
WO2007086879A2 (en) 2005-02-11 2007-08-02 University Of Southern California Method of expressing proteins with disulfide bridges
CN101175757B (zh) 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
CA2617660C (en) * 2005-08-19 2014-03-25 Endocyte, Inc. Multi-drug ligand conjugates
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
EP2029156A4 (de) 2006-05-01 2010-07-21 Univ Southern California Kombinationstherapie zur krebsbehandlung
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
AR061181A1 (es) * 2006-05-25 2008-08-13 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
PE20080102A1 (es) * 2006-05-25 2008-02-11 Bristol Myers Squibb Co Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
WO2008070666A2 (en) 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cpg rich dna and cupredoxins
WO2008098216A2 (en) 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
WO2008101231A2 (en) * 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP2139523B1 (de) * 2007-03-14 2014-10-22 Endocyte, Inc. Konjugate aus folat und tubulysinen zur zielgerichteten wirkstofffreisetzung
US8143415B2 (en) * 2007-05-25 2012-03-27 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
AU2008268432B2 (en) * 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP2209374B1 (de) 2007-10-25 2014-12-03 Endocyte, Inc. Tubulysine und verfahren zu ihrer herstellung
WO2009146152A2 (en) * 2008-04-04 2009-12-03 Emory University Non-myelosuppressive compounds, pharmaceutical compositions thereof, and methods of treatment
AU2009240538B2 (en) * 2008-04-24 2014-08-07 Bristol-Myers Squibb Company Use of Epothilone D in treating Tau-associated diseases including Alzheimer's disease
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2534170B1 (de) 2010-02-12 2017-04-19 Pharmascience Inc. Iap-bir-domänen bindende verbindungen
MX2012013100A (es) 2010-05-18 2013-01-22 Cerulean Pharma Inc Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
US8846006B2 (en) 2011-01-20 2014-09-30 Board Of Regents, The University Of Texas System MRI markers, delivery and extraction systems, and methods of manufacture and use thereof
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
IN2015DN04147A (de) 2012-10-16 2015-10-16 Endocyte Inc
WO2014075391A1 (zh) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
WO2017066606A1 (en) * 2015-10-16 2017-04-20 William Marsh Rice University Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE59610712D1 (de) 1995-11-17 2003-10-16 Biotechnolog Forschung Gmbh Epothilonderivate, herstellung und verwendung
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
CZ303422B6 (cs) 1996-11-18 2012-09-05 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilon C, zpusob jeho výroby a jeho použití jako cytostatik a prostredku pro ochranu rostlin
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
EP1386922B1 (de) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthese von Epitholonen, Zwischenprodukte, Analoga und ihre Verwendung
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
WO1998038192A1 (de) 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Seitenkettenmodifizierte epothilone
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
DE59805900D1 (de) 1997-04-18 2002-11-14 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
PT1001951E (pt) 1997-07-16 2003-02-28 Schering Ag Derivados de tiazolo, processo para a sua preparacao e utilizacao
DE59814067D1 (de) 1997-08-09 2007-09-06 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
KR100669174B1 (ko) 1998-02-05 2007-01-17 노파르티스 아게 유기화합물 함유 조성물
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
EP1140944B1 (de) 1998-12-22 2003-08-27 Novartis AG Epothilonderivate und ihre verwendung als antitumormittel
EA009206B1 (ru) 1999-02-18 2007-12-28 Шеринг Акциенгезельшафт Производные 16-галогенэпотилона и их фармацевтическое использование
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos

Also Published As

Publication number Publication date
EP1589017A3 (de) 2009-04-22
PT1073648E (pt) 2006-12-29
EP1073647B1 (de) 2009-07-08
TR200003036T2 (tr) 2001-01-22
JP4476483B2 (ja) 2010-06-09
CN1142923C (zh) 2004-03-24
PE20000460A1 (es) 2000-06-09
EP1589017A2 (de) 2005-10-26
AU3471699A (en) 1999-11-08
PT1073647E (pt) 2009-07-17
US6399638B1 (en) 2002-06-04
PT1589017E (pt) 2013-03-04
CN1298398A (zh) 2001-06-06
DE69933287T2 (de) 2007-05-03
AR015774A1 (es) 2001-05-16
EP1073648A4 (de) 2003-01-02
AU3382799A (en) 1999-11-08
DK1073648T3 (da) 2007-01-08
AR015007A1 (es) 2001-04-11
CY1109593T1 (el) 2014-08-13
US6380395B1 (en) 2002-04-30
EP1589017B1 (de) 2012-12-05
ES2273484T3 (es) 2007-05-01
CA2329181C (en) 2011-02-22
AU757733B2 (en) 2003-03-06
JP2002512238A (ja) 2002-04-23
ES2400049T3 (es) 2013-04-05
CA2323609A1 (en) 1999-10-28
EP1073648B1 (de) 2006-09-20
WO1999054318A1 (en) 1999-10-28
ES2327803T3 (es) 2009-11-03
ATE435861T1 (de) 2009-07-15
DE69933287D1 (de) 2006-11-02
AU748526B2 (en) 2002-06-06
BR9909795A (pt) 2000-12-26
CY1105836T1 (el) 2011-02-02
DK1589017T3 (da) 2013-03-18
WO1999054319A1 (en) 1999-10-28
EP1073648A1 (de) 2001-02-07
EP1073647A1 (de) 2001-02-07
JP2002512239A (ja) 2002-04-23
DE69941083D1 (en) 2009-08-20
DK1073647T3 (da) 2009-11-09
CA2329181A1 (en) 1999-10-28
EP1073647A4 (de) 2003-01-02

Similar Documents

Publication Publication Date Title
DK1073647T3 (da) 12,13-cyclopropan epothilon-derivater
ATE426598T1 (de) Epothilonderivate
DE69907964D1 (de) 1,2-annelierte chinolinderivate
NO20010193L (no) Tiobenzimidazol-derivater
ATE236136T1 (de) Benzosulfonderivate
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
ATE259810T1 (de) Phenyl-xanthinderivate
NO20010514L (no) Aminometylkarboksylsyre-derivater
TR199802765A3 (tr) Tiyazol türevleri.
DK1140835T3 (da) 3,3-biarylpiperidin- og 2,2-biarylmorpholon-derivater
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
NO20003825L (no) 1,3,4 - oxadiazolonderivater
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
DK1115716T3 (da) 2-phenylpyran-4-on-derivater
ATE233253T1 (de) Chromanderivate
DK1134219T3 (da) Cucloalkylsubstituerede aminomethylpyrrolidinderivater
ATE234839T1 (de) 4,5-azolo-oxindole
DK1060183T3 (da) 5-deoxycytidinderivater
ATE243218T1 (de) 2''-deoxyhygromycinderivate
DE59907635D1 (de) Pyrazolyldioxothiochromanoyl-derivate
DE69805392D1 (de) Thiazol-Derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1073648

Country of ref document: EP